Outpatient Hypertension Management

UW Medicine | Valley Medical Center Grand Rounds January 17, 2024 Jasleen Ghuman, MD

Disclosures

• None


Objectives

- Epidemiology of hypertension
- Timeline of hypertension management guidelines
- Measuring blood pressure
- Current guidelines for hypertension management
 - 2017 ACC/AHA
 - 2017 ACP/AAFP in older adults
 - 2021 KDIGO guidelines for blood pressure management in CKD
 - 2022 AAFP
- Young adults?


Epidemiology

- 1.28 billion adults world-wide aged 30-79 yrs have HTN (>140/90)
- ~ 46% of adults with HTN are unaware
- < <42% of adults with HTN are diagnosed and treated
- 1/5 adults with HTN have it under control
- HTN is the major cause of premature death world-wide

Uncontrolled HTN*: All-cause & CVD mortality *JNC 8: <60 yrs BP <140/90, ≥ 60 yrs BP <150/90




Age-adjusted trend in HTN prevalence among US adults;1999-2018 (NHANES)




HTN defined as SBP >130, DBP >80 or being on anti-hypertensive medications

HTN management trials/guidelines



Herbert & Ibrahim, *Methodist DeBakey Cardiovasc J*, 2022

BP measurement



Drawz PE et al, JAMA Intern Med, 2020 www.uspreventiveservicestaskforce.org


STANDARDISED OFFICE BLOOD PRESSURE MEASUREMENT

TECHNIQUE





PREPARATION



MEASUREMENT




 Both arms
 Higher arm noted for future use
 Repeat 1-2 minutes later

✓ Record SBP/DBP
 ✓ Average
 ≥2 readings
 ≥2 occasions
 ✓ Note time of BP medication



Tell patient the BP verbally & in writing Out of Office BPM can complement Standardised BPM






Can be used to detect white coat HTN / effect and masked HTN

Chapter 1. Blood Pressure Measurement KDIGO 2021 Clinical Practice Guidelines for the Management of Blood Pressure in Chronic Kidney Disease Suppl to KI 99 (2021) 99, S1-S87

Visual Abstract by @Dilushiwijay





Bello NA et al, J Am Heart Assoc, 2018

How to measure your blood pressure at home

Follow these steps for an accurate blood pressure measurement

1. PREPARE

Avoid caffeine, smoking and exercise for 30 minutes before measuring your blood pressure.

Wait at least 30 minutes after a meal.

If you're on blood pressure medication, measure your BP *before* you take your medication.

Empty your bladder beforehand.

Find a quiet space where you can sit comfortably without distraction.



3. MEASURE

Rest for five minutes while in position before starting.

Take two or three measurements, one minute apart, twice daily for seven days.

Keep your body relaxed and in position during measurements.

Sit quietly with no distractions during measurements—avoid conversations, TV, phones and other devices.


Record your measurements when finished.

Content provided by




©2020 American Medical Association. All Rights Reserved. 10/20 MRG15940-6B This Prepare, position, measure handout was adapted with permission of the American Medical Association and The Johns Hopkins University. The original copyrighted content can be found at <u>https://www.ama-assn.org/ama-johns-hopkins-blood-pressure-resources</u>.


www.targetBP.org



HTN management trials/guidelines

Herbert & Ibrahim, Methodist DeBakey Cardiovasc J, 2022






HTN management trials/guidelines

Herbert & Ibrahim, Methodist DeBakey Cardiovasc J, 2022


JNC-8 (2014)

Evidence based recommendations for management of high blood pressure in adults




JNC-8 controversies

- Panel members withdrew
- Not accepted by ACC/AHA, NHLBI, ASH



James, PA et al, JAMA, 2014




HTN management trials/guidelines

Herbert & Ibrahim, Methodist DeBakey Cardiovasc J, 2022

2017 ACC/AHA: <130/80

- SHEP: Systolic hypertension in the elderly program
- HYVET: Hypertension in the very elderly trial
- FEVER: Felodipine event reduction study
- JATOSH: Japanese trial to assess optimum systolic blood pressure in the elderly hypertensive patients
- VALISH: Valsartan in elderly isolated systolic hypertension study
- ACCORD: Action to control cardiovascular risk in diabetes
- SPS-3: Secondary prevention of subcortical strokes study
- SPRINT: Systolic blood pressure intervention trial



HTN management trials/guidelines

Herbert & Ibrahim, Methodist DeBakey Cardiovasc J, 2022


Systolic Blood Pressure Intervention Trial (SPRINT) - Randomized, open-label, multi-center trial


Age ≥ 50 yr, SBP ≥130mm Hg + one risk factor of heart disease (CV dz, CKD, 10-yr Framingham CVD risk score ≥15% or age ≥75 years) Notable exclusions: eGFR <20 mL/min/1.72m ² , h/o stroke, DM, LVEF <35%,					
N = 4678 Intensive treatment SBP <120 mmHg		N = 4683 Standard treatment SBP <140 mmHg			
Median follow-up 3.26 years 1.65% per yr Primary composite outcome of MI, ACS, CVA, HF or death from CV cause 2.19% per yr HR = 0.75, 95% CI [0.64-0.89], p <0.001					
1.03% per yr	Death from any cause HR = 0.73, 95% CI [0.6-0.9], p=0.003		1.4% per yr		
0.25% per yr	Death from CV cause HR = 0.57, 95% CI [0.38-0.85], p=0.005		0.43% per yr		
38.3% of patients	Serious adv HR = 1.04		37.1 % of patients		

SPRINT Research Group, NEJM, 2015

SPRINT - Conclusion

In high-risk, non-diabetic individuals with HTN, including elderly, intensive BP control of SBP <120 vs. <140, reduced CV and all-cause mortality






Office BP vs. out-of- office BP	 Out-of-office BP measurements for diagnosis and titration of medications (COR/LOE: Grade 1/A)
Optimal target BP	 HTN + known CVD or 10-yr ASCVD risk ≥10% : SBP <130 (COR/LOE: 1/B-R), DBP <80 (COR/LOE:1/C-EO) HTN & no additional risk factors: SBP <130 (COR/LOE: 2b/B-NR), DBP <80 (COR/LOE: 2b/C-EO)
Choice of initial medication	
Monotherapy vs. combination therapy	



Office BP vs. out-of- office BP	 Out-of-office BP measurements for diagnosis and titration of medications (COR/LOE:1/A)
Optimal target BP	 HTN + known CVD or 10-yr ASCVD risk ≥10% : SBP <130 (COR/LOE: 1/B-R), DBP <80 (COR/LOE: 1/C-EO) HTN & no additional risk factors: SBP <130 (COR/LOE: 2b/B-NR), DBP <80 (COR/LOE: 2b/C-EO)
Choice of initial medication	 Initiation first line agents: Thiazide diuretics, ACEi/ARB, CCB (COR/LOE: 1/A)
Monotherapy vs. combination therapy	

Office BP vs. out-of- office BP	 Out-of-office BP measurements for diagnosis and titration of medications (COR/LOE:1/A)
Optimal target BP	 HTN + known CVD or 10-yr ASCVD risk ≥10% : SBP <130 (COR/LOE: 1/B-R), DBP <80 (COR/LOE: 1/C-EO) HTN & no additional risk factors: SBP <130 (COR/LOE: 2b/B-NR), DBP <80 (COR/LOE: 2b/C-EO)
Choice of initial medication	 Initiation first line agents: Thiazide diuretics, ACEi/ARB, CCB (COR/LOE: 1/A)
Monotherapy vs. combination therapy	 Co-morbid conditions 2 drugs separate or combination for stage 2 HTN & avg BP >20/10mmHg above target (COR/LOE: 1/C-EO) Stage I HTN, monotherapy acceptable to keep <130/80(COR/LOE:2a/C-EO)



Blood Pressure Categories

SYSTOLIC mm Hg (upper number)		DIASTOLIC mm Hg (lower number)
LESS THAN 120	and	LESS THAN 80
120 - 129	and	LESS THAN 80
130 - 139	or	80 - 89
140 OR HIGHER	or	90 OR HIGHER
HIGHER THAN 180	and/or	HIGHER THAN 120
	(upper number) LESS THAN 120 120 - 129 130 - 139 140 OR HIGHER	(upper number)LESS THAN 120and120 - 129and130 - 139or140 OR HIGHERor


2017 ACP/AAFP

Concern for:

- Conflicts of interest
- Deviation from IOM recommended practices for developing trustworthy guidelines

ACP/AAFP

- Primary care groups declined to participate in ACC/AHA guideline panel
- Did not endorse 2017 ACC/AHA HTN guidelines
- 2017 ACP/AAFP HTN guidelines for older adults with hypertension



2017 ACC/ACP older adults (≥ 60 yrs)

Systematic review of RCT for primary outcome: all-cause mortality, morbidity and mortality related to stroke, major cardiac events (fatal & non-fatal MI, SCD)

Observational data for harms

Treatment of higher (<150 mmHg) vs. lower (\leq 140 mmHg) SBP targets for adults aged \geq 60 yrs with HTN

Qaseem, A et al, Annals Int Med, 2017

2017 ACC/ACP older adults (≥ 60 yrs)

1

Initiate treatment to target SBP <150, to reduce risk of stroke, cardiac events and possibly death (strong recommendation)




Initiate or intensify treatment to target SBP <140 in those with h/o stroke or TIA to reduce recurrence risk (weak recommendation)



Initiate or intensify treatment to target SBP <140 those with high cardiovascular risk based on individual assessment (weak recommendation)


Qaseem, A et al, Annals Int Med, 2017



HTN management trials/guidelines

Herbert & Ibrahim, Methodist DeBakey Cardiovasc J, 2022

Central Illustration for KDIGO 2021 Guideline for the Management of Blood Pressure in Patients with CKD, not receiving dialysis



KDIGO Blood Pressure Workgroup, Kidney Int, 2021

2021 KDIGO – rationale for SBP <120mmHg

CVD leading cause of death in CKD, not ESKD

SPRINT- CV & mortality benefits in non-diabetic CKD

ACCORD – reduction in stroke in diabetes, albeit few patients with eGFR <60mL/min/m²


Meta-analysis – reduction in CV risk proportional to BP lowering

KDIGO Blood Pressure Workgroup, *Kidney Int*, 2021

SPRINT Intensive BP Lowering Reduces GFR But Does Not Increase Injury Biomarkers

INTERVENTION

1-YEAR OUTCOMES



ARTICLE: Effects of Intensive BP Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT

Rakesh Malhotra, Timothy Craven, Walter T. Ambrosius, et al

Am J Kidney Dis (ePub Oct 2, 2018) | DOI: 10.1053/j.ajkd.2018.07.015 | © National Kidney Foundation




ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES

Intensive BP Lowering Reduces GFR But Does Not Increase Injury Biomarkers

INTERVENTION

2-YEAR OUTCOMES



Effect of Intensive Blood Pressure Lowering on Kidney Tubule Injury: Findings From the ACCORD Trial Study Participants Girish N. Nadkarni, Kinsuk Chauhan, Veena Rao, et al

Am J Kidney Dis (ePub Oct 2, 2018) | DOI: 10.1053/j.ajkd.2018.07.016 | © National Kidney Foundation

2022 AAFP



All adults, BP target <140/90mmHg to reduce the risks of all-cause and cardiovascular **mortality** (strong recommendation)



Consider a BP target <135/85 mmHg to reduce the risk of myocardial infarction (weak recommendation)



Potential harms: cost of medications, drug-drug interactions, adverse events (falls, syncope, "AKI")

Coles, S et al, Ann Fam Med, 2023

Guidelines	BP target
2014 JNC-8	<150/90, <140/90
2017 ACC/AHA	<130/80
2017 ACP/AAFP (\geq 60 years)	<150, ≤140
2021 KDIGO for CKD	<120/80, <130/80 (transplant)
2022 AAFP (all adults)	<140/90, <135/85

Study objectives




The STEP study was conducted to provide new evidence on the benefits of BP lowering in older patients with hypertension. Specifically, it examined whether intensive treatment targeting a SBP below 130 mmHg could reduce the risk of cardiovascular disease compared with a SBP target below 150 mmHg.




Who and what?






Primary endpoint




Relative risk reduction: 26% HR: 0.74 (95% CI: 0.60-0.92)



Patients (60-80 years old)

from baseline (mmHg) Average SBP reached (mmHg) 126.7 135.9

Secondary endpoints



STEP Study - 2021

STEP study #ESCCongress

Intensive vs. standard blood pressure control among older hypertensive patients


Conclusion



Active control of systolic blood pressure (SBP) to below 130 mmHg in older hypertensive patients, as compared with below 150 mmHg, resulted in a lower incidence of major CV events, with no increase in renal injuries.

Young adults

- Hypertension without elevated 10- yr ASCVD risk
 - Understudied, lower-risk group will require very long follow-up to see clinically significant results
 - No trial evidence supporting decrease in CVD morbidity & mortality
- Observational data: high life-time risk, benefit of BP control early in life
- In the absence of clear guidelines for younger patients with low 10-yr risk
 - Focus on life-time risk
 - Prevention of progression of HTN




Yano, Y et al, JAMA, 2018

Young adults

2017 ACC/AHA

Adults with an **elevated BP or stage 1 hypertension who have an estimated 10-year ASCVD risk less than 10%** should be managed with nonpharmacological therapy and have a repeat BP evaluation within 3 to 6 months




2021 AHA Scientific statement

Medications if BP >130/80 mmHg after 6 months of lifestyle therapy System changes are necessary

Jones DW, et al, Hypertension, 2021

5 years post-SPRINT



Jaeger BC, et al, JAMA Cardiol, 2022

Bottom-line

Most adults <130/80 CKD <120/80 (standardized office BP, out-of-office BP)

Lifestyle modifications +/- pharmacological therapy Elevated BP or stage I: Single agent (ARB, CCB, thiazide) Low dose combination

Stage 2 and/or escalation: Combination (ARB/CCB, CCB/thiazide, ARB/thiazide)

*co-morbid conditions, drug allergies, resistant hypertension, individualized risk vs. benefit if AE, race – social construct

Take home points

Ų

Shared decision making

Effective guidelines are followed by patients and practitioners



Guidelines should not replace clinical judgement

Standardized office blood pressure > routine office blood pressure


Combination therapy of anti-HTN to achieve target BP in an individual patient

Lifestyle modifications



Overcoming clinical inertia for improved patient outcomes

Questions




Supplementary slides

JN JAMA Network"

SPRINT MIND

QUESTION Does intensive blood pressure control compared with standard control reduce the occurrence of dementia?

CONCLUSION This randomized clinical trial of adults with hypertension found that intensive systolic blood pressure (SBP) control (target <120 mm Hg) did not significantly reduce the risk of probable dementia.



The SPRINT MIND Investigators for the SPRINT Research Group. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial [published January 28, 2019]. JAMA. doi:10.1001/jama.2018.21442


Heart failure events in a clinical trial on arterial hypertension: new insights into the SPRINT trial

SPRINT trial population	Intervention	Outcome		
	intensive systolic blood pressure lowering < 120 mmHg	1) composite clinical endpoint: myocardial infarction, stroke, acute coronary syndrome, cardiovascular death = primary SPRINT outcome excluding heart failure events		
¹π¹π¹π ¹ π ¹ π ¹ π ¹ π ¹	randomization 1:1	2) cardiovascular deaths (excluding heart failure)		
post-hoc analysis	standard systolic blood pressure			
9361 participants	lowering < 140 mmHg	3) all-cause deaths (excluding heart failure)		
Results	4.4%	Hazard ratio:		
Composite clinical endpoint	5.5%	0.79, 95% CI 0.66–0.95		
Cardiovascular death	0.4%	0.52, 95% CI 0.33–0.81		
(excluding heart failure)	1.2%	0.32, 93/0 01 0.33 0.01		
All-cause death	3.1%	0.73, 95% CI 0.59–0.90		
(excluding heart failure)	4.3%			
■ intensive SBP lowering <10	■ intensive SBP lowering <120 mm Hg ■ standard SBP lowering <140 mm Hg			

■ intensive SBP lowering <120 mm Hg ■ standard SBP lowering <140 mm Hg

Conclusions

Intensive lowering of systolic blood pressure (to <120 mm Hg) using the SPRINT methodology is associated with a 21% reduced risk (p = 0.012) of a composite endpoint (myocardial infarction, acute coronary syndrome other than myocardial infarction, stroke, and cardiovascular death) compared with the standard treatment (lowering the target SBP to <140 mm Hg)




2010

outcome of fatal and nonfatal major cardiovascular events.

ACCORD Study Group., NEJM, 2010. 362(17):1575-1585.


M Visualmed



Asayama, K, Nature Hypertension Research, 2023

STOP-ACEi

Does the discontinuation of RAS inhibitors improve eGFR in patients with advanced CKD?



significant between-group difference in the long-term rate of eGFR decline.

Visual Abstract by: Dana Larsen, MD 🅑 @dana_m_larsen 🛇

The STOP-ACEi investigators, NEJM, 2022

29

[‡]NephJC

